Neurocrine Biosciences (NASDAQ:NBIX) Posts Quarterly Earnings Results

Neurocrine Biosciences (NASDAQ:NBIX) posted its quarterly earnings results on Monday. The company reported $3.29 EPS for the quarter, topping the consensus estimate of $1.91 by $1.38, FiscalAI reports. Neurocrine Biosciences had a net margin of 18.98% and a return on equity of 24.11%. The firm had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.04 billion. During the same period last year, the firm posted $2.04 earnings per share. The business’s revenue was up 41.3% compared to the same quarter last year.

Here are the key takeaways from Neurocrine Biosciences’ conference call:

• Record third-quarter performance: Net product sales exceeded $1.1 billion, up more than 40% year over year, while operating profitability and non-GAAP earnings also reached records.
• INGREZZA sales rose 17% to $801 million, prompting the company to raise full-year guidance to $2.9 billion–$2.925 billion. Management expects double-digit volume growth in 2027 to offset mid- to high-single-digit net pricing pressure.
• CRENESSITY sales reached $211 million, supported by steady patient additions, favorable reimbursement, and strong persistence; more than 15% of diagnosed classic CAH patients have now been prescribed the drug. The company is pursuing a study in children under age four that could expand the label.
• VYKAT XR sales reached $107 million, but management acknowledged that recent external safety-related events may delay its growth trajectory. The company expects continued monitoring, education, and a 2027 study in PWS patients with complex comorbidities, while discontinuation trends remain an area it is still evaluating.
• Neurocrine highlighted a catalyst-rich 2027, including Phase III readouts for osavampator in major depressive disorder and direclidine in schizophrenia, plus progress in Alzheimer’s disease, obesity, and Friedreich’s ataxia. The company ended the quarter with approximately $800 million in cash and retains flexibility for disciplined business development.

Neurocrine Biosciences Stock Up 13.4%

Shares of Neurocrine Biosciences stock opened at $164.85 on Wednesday. The company has a market cap of $16.76 billion, a PE ratio of 24.46, a P/E/G ratio of 0.64 and a beta of 0.36. The business has a 50 day moving average of $146.72 and a 200 day moving average of $147.60. Neurocrine Biosciences has a 52 week low of $122.14 and a 52 week high of $186.12.

Neurocrine Biosciences News Roundup

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Third-quarter revenue grew 41% year over year to $1.12 billion, beating expectations, while EPS of $3.29 exceeded the $1.91 consensus cited in the report. Product sales topped $1 billion for the first time, and Neurocrine raised its 2026 INGREZZA sales forecast to $2.9–$2.925 billion, citing strong demand and portfolio growth. Third-quarter results
• Positive Sentiment: Several analysts lifted price targets after the earnings report: Canaccord raised its target to $220, Piper Sandler to $215, and RBC to $190; Morgan Stanley raised its target to $185 while retaining an equal-weight rating.
• Neutral Sentiment: Neurocrine has started a Phase 2 Alzheimer’s study, adding a potential longer-term pipeline opportunity, though the supplied report gives few details on the trial. Alzheimer’s study
• Negative Sentiment: Director George J. Morrow sold 15,000 shares across reported transactions on October 30 and November 2–3. The sales were made under a pre-arranged Rule 10b5-1 plan, which may reduce concern about the timing, and he retained 10,386 shares.
• Negative Sentiment: A risk disclosure flagged integration challenges and legacy liabilities that could limit the value Neurocrine captures from its Soleno acquisition, creating uncertainty around the deal’s eventual contribution.

Insider Buying and Selling

In related news, insider David Boyer sold 826 shares of Neurocrine Biosciences stock in a transaction on Monday, September 14th. The shares were sold at an average price of $157.45, for a total value of $130,053.70. Following the sale, the insider owned 8,722 shares in the company, valued at $1,373,278.90. The trade was a 8.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director George J. Morrow sold 7,200 shares of the company’s stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $166.37, for a total transaction of $1,197,864.00. Following the completion of the transaction, the director owned 10,386 shares of the company’s stock, valued at $1,727,918.82. This trade represents a 40.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 18,137 shares of company stock valued at $2,829,332 over the last quarter. 4.60% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on NBIX. TD Cowen lifted their price objective on Neurocrine Biosciences from $200.00 to $220.00 and gave the stock a “buy” rating in a report on Friday, July 31st. UBS Group lowered their target price on Neurocrine Biosciences from $231.00 to $214.00 and set a “buy” rating for the company in a research note on Tuesday, September 29th. Stifel Nicolaus increased their target price on Neurocrine Biosciences from $188.00 to $215.00 and gave the company a “buy” rating in a report on Friday, July 31st. Guggenheim initiated coverage on Neurocrine Biosciences in a research report on Tuesday, October 6th. They set a “buy” rating and a $207.00 price target on the stock. Finally, Citigroup raised their price target on Neurocrine Biosciences from $249.00 to $253.00 and gave the stock a “buy” rating in a research report on Thursday, September 3rd. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $201.55.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.